{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:11:10Z","timestamp":1789996270659,"version":"4.0.1"},"reference-count":16,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Solithromycin, a fourth-generation macrolide (a fluoroketolide with enhanced activity against macrolide-resistant bacteria due to interaction with three ribosomal sites) and the first fluoroketolide, was tested against a 2014 collection of 6,115 isolates, including\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Streptococcus pneumoniae<\/jats:named-content>\n            (1,713 isolates),\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Haemophilus influenzae<\/jats:named-content>\n            (1,308),\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Moraxella catarrhalis<\/jats:named-content>\n            (577),\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (1,024), and beta-hemolytic streptococci (1,493), by reference broth microdilution methods. The geographic samples included 2,748 isolates from the United States, 2,536 from Europe, 386 from Latin America, and 445 from the Asia-Pacific region. Solithromycin was observed to be very active against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. pneumoniae<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.008\/0.12 \u03bcg\/ml), demonstrating 2-fold greater activity than telithromycin (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.015\/0.25 \u03bcg\/ml) and 16- to &gt;256-fold greater activity than azithromycin (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/&gt;32 \u03bcg\/ml), with all strains being inhibited at a solithromycin MIC of \u22641 \u03bcg\/ml. Against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">H. influenzae<\/jats:named-content>\n            , solithromycin showed potency identical to that of telithromycin (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 1\/2 \u03bcg\/ml), and both of these compounds were 2-fold less active than azithromycin (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.5\/1 \u03bcg\/ml). All but one of the\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. catarrhalis<\/jats:named-content>\n            isolates were inhibited by solithromycin at \u22640.25 \u03bcg\/ml. Solithromycin inhibited 85.3% of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            isolates at \u22641 \u03bcg\/ml, and its activity was lower against methicillin-resistant (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/&gt;32 \u03bcg\/ml) than against methicillin-susceptible (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.06 \u03bcg\/ml) isolates. Little variation in solithromycin activity was observed by geographic region for the species tested. Solithromycin was very active against beta-hemolytic streptococci (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.015\/0.03 \u03bcg\/ml), and all isolates were inhibited at MIC values of \u22640.5 \u03bcg\/ml. In conclusion, solithromycin demonstrated potent activity against global and contemporary (2014) pathogens that represent the major causes of community-acquired bacterial pneumonia. These data support the continued clinical development of solithromycin for the treatment of this important indication.\n          <\/jats:p>","DOI":"10.1128\/aac.00185-16","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T03:59:15Z","timestamp":1459828755000},"page":"3662-3668","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Results from the Solithromycin International Surveillance Program (2014)"],"prefix":"10.1128","volume":"60","author":[{"given":"David J.","family":"Farrell","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152606779025842"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01662-09"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/592972"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000253059.84602.c3"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1907.121830"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.10.013"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02316-12"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2010.08.010"},{"key":"e_1_3_2_10_2","volume-title":"Abstr 55th Intersci Conf Antimicrob Agents Chemother","author":"Biedenbach DJ","year":"2015","unstructured":"Biedenbach DJ, Farrell DJ, Sader HS, Jones RN. 2015. Antimicrobial activity of a new fluoroketolide solithromycin (CEM-101) tested against fastidious Gram-negative community-acquired bacterial pneumonia pathogens, abstr 217. Abstr 55th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-09"},{"key":"e_1_3_2_12_2","unstructured":"Roblin PM Kohloff SA Hammerschlag MR. 2008. In vitro activity of CEM101 a new ketolide antibiotic against Chlamydia trachomatis and Chlamydia pneumoniae abstr F1-3978. Abstr 48th Intersci Conf Antimicrob Agents Chemother."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01639-13"},{"key":"e_1_3_2_14_2","unstructured":"CLSI. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: 10th ed. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_15_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 25th informational supplement","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_16_2","volume-title":"Breakpoint tables for interpretation of MICs and zone diameters, version 5.0, January 2015","author":"EUCAST","year":"2015","unstructured":"EUCAST. 2015. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0, January 2015. European Committee on Antimicrobial Susceptibility Testing."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00185-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00185-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:47:06Z","timestamp":1645476426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00185-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1128\/AAC.00185-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00185-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"2016-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}